Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study

• DOI: 10.1007/s12325-021-02016-x
• Publication Date: 2022-01-03T02:02:22Z
• Authors: Kurt de Vlam; Adrien Nzeusseu T...; Marie-Joëlle Kaiser; Johan Vanhoof; Philip Remans; Marthe Van den Be...; Silvana Di Romana; Filip Van den Bosch; Rik Lories
• Keywords: Apremilast

Apremilast is approved for the treatment of psoriasis and psoriatic arthritis (PsA). Real-world evidence on efficacy safety apremilast in clinical practice limited. We assessed use patients with PsA Belgium practice. The multicentre, observational, prospective APOLO study enrolled active initiating between April 2017 December 2018. Primary outcome was Response Criteria (PsARC) after 6 months treatment. Secondary outcomes included Impact Disease 12 (PsAID12) Health Assessment Questionnaire Disability Index (HAQ-DI). Disease-specific patient-reported (PROs) were analysed who received within 30 days prior to their inclusion completed at least 150 (reference set [REF]). Of 107 study, 106 one dose 69 REF. PsARC response achieved by 43.5% (30/69) REF month 6; mean global composite scores including 68-joint count pain/tenderness (68-TJC) 66-joint swelling (66-SJC) improved, 27% 42% 68-TJC 66-SJC > 0 baseline had complete joint resolution, respectively. Mean PsAID12 HAQ-DI decreased months, indicating improved quality life. well tolerated reported adverse events line known profile. Results from indicate that Belgian improves signs symptoms as patient NCT03096990.